StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.47−0.25 (-3.24%)

Close on Nov 20, 2026Market cap $1.23BP/E –Yield –

Novavax free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Novavax's free cash flow for the twelve months ending Sep 30, 2022 was -$722.93M, down 259.4% year over year. For fiscal 2021 it was $265.46M. The highest annual figure on record is $265.46M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2021Dec 31, 2021$265.46M–
FY2020Dec 31, 2020-$97.16M–
FY2019Dec 31, 2019-$138.48M–
FY2018Dec 31, 2018-$186.20M–
FY2017Dec 31, 2017-$148.67M–
FY2016Dec 31, 2016-$276.97M–
FY2015Dec 31, 2015-$144.36M–
FY2014Dec 31, 2014-$74.28M–
FY2013Dec 31, 2013-$51.14M–
FY2012Dec 31, 2012-$22.57M–
FY2011Dec 31, 2011-$24.24M–
FY2010Dec 31, 2010-$34.41M–
FY2009Dec 31, 2009-$33.58M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2022Sep 30, 2022-$63.34M–
Q2 FY2022Jun 30, 2022-$195.48M-251.2%
Q1 FY2022Mar 31, 2022-$105.34M-116.2%
Q4 FY2021Dec 31, 2021-$358.77M–
Q3 FY2021Sep 30, 2021-$154.33M–
Q2 FY2021Jun 30, 2021$129.26M+15.5%
Q1 FY2021Mar 31, 2021$649.30M–
Q4 FY2020Dec 31, 2020-$170.58M–
Q3 FY2020Sep 30, 2020-$15.22M–
Q2 FY2020Jun 30, 2020$111.87M–
Q1 FY2020Mar 31, 2020-$23.23M–
Q4 FY2019Dec 31, 2019-$23.96M–
Q3 FY2019Sep 30, 2019-$32.62M–
Q2 FY2019Jun 30, 2019-$30.49M–
Q1 FY2019Mar 31, 2019-$51.41M–
Q4 FY2018Dec 31, 2018-$45.78M–
Q3 FY2018Sep 30, 2018-$33.91M–
Q2 FY2018Jun 30, 2018-$40.28M–
Q1 FY2018Mar 31, 2018-$66.23M–
Q4 FY2017Dec 31, 2017-$44.05M–
Q3 FY2017Sep 30, 2017-$45.40M–
Q2 FY2017Jun 30, 2017-$13.64M–
Q1 FY2017Mar 31, 2017-$45.58M–
Q4 FY2016Dec 31, 2016-$67.74M–
Q3 FY2016Sep 30, 2016-$66.32M–

More Novavax figures

See a number that looks wrong?